Mindset Pharma Inc (CSE:MSET) (OTCQB:MSSTF) CEO James Lantier and Chief Scientific Officer Dr Joseph Araujo tell Proactive that InterVivo Solutions (IVS) had released the first data set as part of its jointly developed advanced Cooperative Psychedelics Evaluation Platform (COPE) program.
Lanthier says the program, launched in March, aims to create the world's first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs. Dr Araujo says preliminary data focused on psilocybin/psilocin and shows that clinical exposure levels reported in humans correlate to exposure and efficacy measures observed in mice - validating the predictive value of IVS's selected behavioural assays and animal models.